FDA Approves Precision Duo for Aggressive Form of Lung Cancer

PALO ALTO, CA – June 11, 2026 – The U.S. Food and Drug Administration has approved a powerful new combination in the fight against a particularly aggressive form of lung cancer, marking a significant strategic victory for Guardant Health and its partner, Boehringer Ingelheim. The agency greenlit Guardant Health’s Guardant360 CDx liquid biopsy as the essential companion diagnostic for Boehringer Ingelheim's HERNEXEOS® (zongertinib), the first targeted therapy approved as an initial treatment for adults with advanced non-small cell lung cancer (NSCLC) driven by specific HER2 mutations.

This dual approval creates a new, streamlined pathway for identifying and treating patients with HER2 (ERBB2)-mutant NSCLC, a condition historically associated with a poor prognosis and limited therapeutic options. For the first time, clinicians can use a simple blood draw to pinpoint patients who can benefit from a highly effective oral therapy, representing a pivotal shift from broad-stroke chemotherapy to personalized, biomarker-driven care.

A Breakthrough for a High-Need Patient Population

Non-small cell lung cancer is the most common type of lung cancer, but HER2-mutant NSCLC, which accounts for 1-4% of cases, has long been a clinical challenge. This subtype is known for its aggressive behavior and a high propensity for spreading to the brain. Before this approval, newly diagnosed patients had no targeted therapies and typically relied on platinum-based chemotherapy, which often yielded suboptimal results.

The approval of HERNEXEOS, a selective tyrosine kinase inhibitor (TKI), fundamentally alters this landscape. The drug's accelerated approval was based on compelling data from the Beamion LUNG-1 trial, which demonstrated remarkable efficacy. In treatment-naïve patients, HERNEXEOS achieved a confirmed objective response rate (ORR) of 76-77%, with a median progression-free survival of 14.4 months. These results, published in The New England Journal of Medicine, signal a durable and meaningful clinical benefit. Critically, the therapy also showed an intracranial objective response rate of 47%, addressing the significant unmet need for treatments that can penetrate the central nervous system.

The FDA's decision was expedited through its Real-Time Oncology Review (RTOR) program and was part of the Commissioner's National Priority Review Voucher pilot, underscoring the agency's recognition of the drug's potential to address a serious unmet medical need. Furthermore, the American Society of Clinical Oncology (ASCO) has already updated its living guidelines to include zongertinib as a recommended option, paving the way for rapid clinical adoption.

The Power of a Simple Blood Draw

The strategic linchpin of this new treatment paradigm is Guardant360 CDx. The liquid biopsy analyzes circulating tumor DNA (ctDNA) from a patient's blood to detect the specific HER2 tyrosine kinase domain activating mutations that make them eligible for HERNEXEOS. This approach circumvents the significant challenges associated with traditional tissue biopsies, which can be invasive, risky, and often fail to yield sufficient material for comprehensive genomic profiling in advanced lung cancer patients.

“This approval highlights the growing impact of liquid biopsy across advanced cancer care and underscores the utility of Guardant360 CDx to ensuring more patients can be matched to the right therapy at the right time,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “Guardant360 CDx has been at the forefront of enabling comprehensive genomic profiling through a simple blood draw, helping clinicians identify actionable mutations in genes such as HER2 with speed and accuracy.”

The speed and convenience of blood-based testing can dramatically shorten the time from diagnosis to treatment, a critical factor when managing aggressive cancers. For Boehringer Ingelheim, the partnership ensures that its breakthrough therapy can reach the right patients efficiently.

“Companion diagnostics are essential to personalized lung cancer care, guiding biomarker-driven treatment decisions,” added Vicky Brown, U.S. Therapeutic Area Head for Oncology and Emerging Areas at Boehringer Ingelheim. “Guardant360 CDx will help identify patients with HER2-mutant advanced non-small cell lung cancer and connect eligible patients to the appropriate targeted therapy when timely treatment decisions matter most.”

Solidifying Leadership in a Competitive Market

For Guardant Health, this latest approval is more than just another regulatory milestone; it is a significant strategic move that reinforces its leadership in the competitive precision oncology diagnostics market. This marks the 27th global companion diagnostic indication for the Guardant360 platform, a testament to its broad utility and deep integration into the fabric of modern cancer care. Each new CDx approval not only drives testing volume but also strengthens the company's moat against competitors like Foundation Medicine, another major player in the liquid biopsy space.

By becoming the designated diagnostic for the first targeted initial therapy in this specific lung cancer subtype, Guardant Health secures a crucial position in the clinical workflow. The approval expands its platform's coverage by Medicare and commercial payers, which already represents over 300 million covered lives, further solidifying its revenue base and demonstrating its value proposition to both clinicians and pharmaceutical partners.

This successful collaboration with Boehringer Ingelheim exemplifies Guardant Health's core business strategy: embedding its technology into the development and commercialization of next-generation cancer therapies. As more targeted drugs enter the pipeline, the demand for reliable, fast, and comprehensive genomic profiling will only grow, positioning the Palo Alto-based company for continued expansion and influence within the oncology ecosystem.